XTL Biopharmaceuticals Regains Full Nasdaq Compliance, Resolving Multiple Delisting Threats
XTLB sits 45% above its 52-week low of $2.01.
Summary
XTL Biopharmaceuticals announced it has regained full compliance with all Nasdaq listing rules, resolving previous delisting threats related to bid price, periodic filings, and minimum stockholders' equity.
Key Events · Corporate Governance and Compliance · XTLB
-
Regained Nasdaq Compliance
The company received a letter from Nasdaq confirming it has regained compliance with Listing Rules 5101 (Public Interest), 5250(c)(1) (Periodic Filing), 5550(a)(2) (Bid Price), and 5550(b)(1) (Equity).
-
Met Bid Price Requirement
Compliance was achieved by maintaining a closing bid price above $1.00 for at least 20 consecutive trading days as of July 13, 2026.
-
Filed Annual Report
The company filed its Form 20-F for the fiscal year ended December 31, 2025, on June 30, 2026, addressing the periodic filing deficiency.
-
Achieved Minimum Equity
Following the acquisition of Psyga Bio Ltd. and a subsequent equity raise, the company now has a minimum of $2.5 million in stockholders' equity.
Analysis · XTLB · Life Sciences
XTL Biopharmaceuticals has successfully resolved multiple Nasdaq delisting issues, including bid price, periodic filing, and minimum equity requirements. This positive development removes a significant overhang and allows the company to continue its strategic pivot following the Psyga Bio acquisition. However, the company will be subject to a one-year mandatory monitoring period, meaning any future non-compliance with the Equity Rule will result in immediate delisting proceedings without further cure periods.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.2% of the 386 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XTLB was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $2.01 to $10.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.